Active Ingredient History
Mitoxantrone (NOVANTRONE) is a synthetic antineoplastic anthracenedione. Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. It has a cytocidal effect on both proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity. Mitoxantrone has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen pre sentation, as well as the secretion of interferon gamma, TNFα, and IL-2. NOVANTRONE is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). NOVANTRONE in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. NOVANTRONE in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Leukemia, Myeloid, Acute (approved 1987)
Multiple Sclerosis, Chronic Progressive (approved 1987)
Prostatic Neoplasms (approved 1987)
Breast Neoplasms (Phase 3)
Burkitt Lymphoma (Phase 2)
Carcinoma, Hepatocellular (Phase 1)
Demyelinating Autoimmune Diseases, CNS (Phase 4)
Down Syndrome (Phase 3)
Hematopoietic Stem Cell Transplantation (Phase 2)
HIV Infections (Phase 2)
Leukemia (Phase 3)
Leukemia, B-Cell (Phase 2)
Leukemia, Biphenotypic, Acute (Phase 2)
Leukemia, Eosinophilic, Acute (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 4)
Leukemia, Lymphoid (Phase 2)
Leukemia, Monocytic, Acute (Phase 2/Phase 3)
Leukemia, Myeloid (Phase 3)
Leukemia, Myeloid, Acute (Phase 4)
Leukemia, Myelomonocytic, Acute (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 1)
Leukemia, Prolymphocytic (Phase 2)
Leukemia, Prolymphocytic, T-Cell (Phase 2)
Leukemia, Promyelocytic, Acute (Phase 4)
Leukemia, T-Cell (Phase 2)
Lung Diseases (Phase 3)
Lymphoma (Phase 3)
Lymphoma, Extranodal NK-T-Cell (Phase 2)
Lymphoma, Follicular (Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 3)
Lymphoma, T-Cell (Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 3)
Multiple Myeloma (Phase 4)
Multiple Sclerosis (Phase 3)
Multiple Sclerosis, Chronic Progressive (Phase 3)
Multiple Sclerosis, Relapsing-Remitting (Phase 2)
Myelitis, Transverse (Phase 4)
Myelodysplastic Syndromes (Phase 3)
Myeloproliferative Disorders (Phase 3)
Neoplasm Metastasis (Phase 1)
Neoplasms ()
Neuromyelitis Optica (Phase 4)
Neutropenia (Phase 3)
Ovarian Neoplasms (Phase 3)
Pain (Phase 3)
Pancreatic Neoplasms (Phase 2)
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)
Prognosis (Phase 2)
Prostatic Neoplasms (Phase 3)
Quality of Life (Phase 3)
Sarcoma (Phase 1)
Sarcoma, Kaposi (Phase 2)
Sarcoma, Myeloid (Phase 3)
Small Cell Lung Carcinoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 1)
Stomach Neoplasms (Phase 1)
Therapeutics (Phase 1/Phase 2)
T-Lymphocytes (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
